Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GoldenCare
- Development stage
- Unknown
- Lead developer
- CDA Research Group
- Administration
- Intravaginal
01
Overview
GoldenCare is a copper-based intravaginal device developed by CDA Research Group for the treatment of symptomatic bacterial vaginosis (BV). The device functions by releasing copper ions, which possess broad-spectrum antimicrobial properties, into the vaginal environment to address the bacterial imbalance (dysbiosis) characteristic of BV. This approach serves as a non-antibiotic alternative to standard treatments like metronidazole. A Phase 2 proof-of-concept study (NCT01762670) was conducted to evaluate the safety and efficacy of the device compared to oral metronidazole, assessing its ability to restore healthy vaginal flora.
- Brand names
- GoldenCare
- Other names
- GoldenCare copper intravaginal device
Beyond the preview
Go deeper on GoldenCare.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GoldenCare.